一心为民 全心服务 关于使用部分暂时闲置 2018 年公开发行可转换公司债券 募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置2018年公开发行可转换公司债券募集资金进行现金管理的议 案》，同意公司使用额度不超过人民币3.25亿元的2018年公开发行可转换公司债券的暂时闲置 募集资金进行现金管理（包括但不限于购买一年期以内的固定收益型或保本浮动收益型理财产 品、大额存单、定期存款、通知存款、协定存款等），以上额度为在投资期限内任一时点的现 金管理金额(含前述投资的收益进行再投资的相关金额)不超过3.25亿元人民币。在上述额度内， 资金可以滚动使用，在额度范围内授权董事长具体办理实施相关事项。独立董事、保荐机构对 上述议案发表了审查意见。 近日，公司与上海浦东发展银行股份有限公司昆明分行签订了《对公结构性存款产品合同》， 于 2025 年 6 月 30 日使用部分暂时闲置募集资金人民币 8,900 万元购买 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-043 号 一心堂药业集团股份有限公司 一心为民 全心服务 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 近日，公司与中国建设银行股份有限公司昆明滇龙支行签订了《中国建设银行人民币单位 协定存款合同》，现将有关情况公告如下： | 签约银 行名称 | 产品名称 | 基本存款 额度（万 | 收益类型 | 合同起始日 | 合同到期日 | 计息方式 | | --- ...

Core Viewpoint - The company, Lao Bai Xing Pharmacy, has experienced significant fluctuations in performance over recent years, with stable growth in gross profit margin despite a decline in net profit and revenue growth slowdown. The company faces challenges from industry competition and regulatory changes in the healthcare sector [2][4]. Financial Performance - Revenue for the years 2022 to 2024 was reported as follows: 20.176 billion, 22.437 billion, and 22.358 billion RMB, with year-on-year changes of 28.54%, 11.21%, and -0.36% respectively. Net profit for the same period was 0.785 billion, 0.929 billion, and 0.519 billion RMB, with changes of 17.29%, 18.35%, and -44.13% respectively [2]. - The overall gross profit margin for the years was 31.88%, 32.56%, and 32.50% [2]. Business Strategy and Market Conditions - The company has been increasing the number of self-built and franchised stores to enhance market share, with total store numbers reaching 15,277 in 2024, up from 13,574 in 2023 and 10,783 in 2022 [6]. - The company is also focusing on online sales channels, with public domain B2C and O2O sales accounting for 10.3% of total revenue in 2024, up from 9.3% in 2023 and 6.6% in 2022 [6]. - The company has adjusted its product strategy to focus more on traditional Chinese and Western medicine, with sales of traditional Chinese and Western medicine accounting for 77.5% of total revenue in 2024 [7]. Industry Challenges - The retail pharmacy market is facing a slowdown in growth, with the total retail pharmacy market sales reaching 528.2 billion RMB in 2024, a year-on-year decline of 2.2% [5]. - The industry is experiencing increased competition, with a total of 675,000 pharmacies in China as of the end of 2024, serving an average of 2,000 people per pharmacy, compared to 5,000 in the United States [5]. Goodwill and Impairment - As of the end of 2024, the company's goodwill balance was 5.756 billion RMB, accounting for 27.35% of total assets. The company recognized a goodwill impairment provision of approximately 0.108 billion RMB for the year [2]. - The company classifies its goodwill based on regional divisions, and the impairment testing process is conducted in accordance with accounting standards [8][10]. Operational Efficiency - The company has implemented measures to improve operational efficiency, including restructuring product selection strategies, enhancing digital product introductions, and optimizing supply chain costs [7]. - The company’s gross profit margin has shown a continuous increase, with a comprehensive gross profit margin of 36.4% in 2024, up from 35.7% in 2023 [7].

Summary of the IP Industry Conference Call Industry Overview - The IP derivative market is experiencing rapid growth, with revenue from derivatives surpassing that of the IP itself, indicating a significant potential for expansion in the market [1][2] - The IP industry chain consists of three segments: upstream content creators (movies, novels, games), midstream product developers (blind boxes, plush toys, cards), and downstream distribution channels (dealers, retail chains, secondary markets) [1][3] Key Insights - The demand for emotional value products varies by consumer demographics, with higher age groups favoring trendy toys and younger audiences gravitating towards card games [1][5] - Notable investment targets include companies in the trendy toy sector like Pop Mart, plush toy brands like Labubu and Jellycat, card game companies like Kayo, and entertainment consumer goods firms like Yadea Electric [1][6] Market Dynamics - Midstream product companies earn 50%-60% of consumer spending, with profit margins highly dependent on product categories; card products have a margin of about 70%, while trendy toys and plush toys range from 40%-70% [1][10] - The IP industry is recognized as a lucrative business, with the derivative products accounting for more than 50% of revenue in overseas markets [2] Future Prospects - The Chinese derivative market is expected to maintain high growth in the coming years, with companies like Pop Mart and Kayo leading the way [3][14] - Emerging companies are exploring new product categories such as food toys and card games, indicating a trend towards diversification in product offerings [14][24] Noteworthy Companies - **Pop Mart**: Demonstrates strong performance in IP incubation and operation, with significant revenue from major IPs like Labubu, and a successful global market presence [16] - **Aofei Entertainment**: Leverages a wide range of channels and has developed national-level IPs across various product categories [17][18] - **Ali Pictures**: Operates the largest IP licensing platform in China, showing rapid growth in sales and a strong portfolio of global IP resources [19] - **Shanghai Film**: Holds a diverse portfolio of classic IPs and is actively pursuing derivative product development [20] - **Kayo**: Plans to go public, with a focus on collectible card games and a projected revenue of 10 billion in 2024 [25] Additional Insights - The secondary market allows consumers to trade products with platforms taking a small commission, while self-operated channels can cover the entire industry chain [8] - The operational success of content stores is closely tied to location and product selection, affecting profitability [9] - Companies are increasingly diversifying their product lines, blurring the lines between different categories [24] Conclusion The IP industry is poised for significant growth, driven by increasing consumer demand for emotional value products and the successful strategies of key players in the market. The diversification of product offerings and the expansion into new categories will further enhance the industry's potential.

Core Points - The CS Internet Healthcare Index (CS互医疗) experienced a slight decline of 0.09%, closing at 2592.79 points with a trading volume of 7.224 billion [1] - Over the past month, the index has increased by 0.65%, but it has decreased by 8.75% over the last three months, while year-to-date it has risen by 9.74% [1] - The index reflects the performance of representative companies providing hardware, software, or services for medical information and intelligence, with a base date of June 29, 2012, set at 1000.0 points [1] Index Composition - The top ten weighted companies in the index are: Lepu Medical (5.51%), Yixintang (5.2%), Laobaixing (5.19%), Haier Biomedical (5.11%), Jiuyuan Yinhai (5.11%), Yaoyigou (5.1%), Aier Eye Hospital (5.03%), Sichuang Medical (5.02%), Jiuzhoutong (5.02%), and Chuangye Huikang (5.02%) [1] - The market share of the index's holdings is divided between Shenzhen Stock Exchange (55.54%) and Shanghai Stock Exchange (44.46%) [1] - In terms of industry distribution, the index's holdings consist of 65.51% in healthcare, 29.47% in information technology, and 5.02% in communication services [1] Index Adjustment - The index samples are adjusted quarterly, with adjustments occurring in the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] Fund Tracking - Public funds tracking the CS Internet Healthcare Index include Huatai-PineBridge CS Internet Healthcare A and Huatai-PineBridge CS Internet Healthcare C [3]

Core Viewpoint - Yixin Pharmaceutical Group Co., Ltd. has approved an investment by its wholly-owned subsidiary, Guizhou Hongxiang Yixintang Pharmaceutical Chain Co., Ltd., to acquire land use rights and associated structures for a total investment of RMB 32.8 million [2]. Group 1: Investment Details - The investment involves acquiring land use rights and buildings located at No. 13, Longdongbao Food Industrial Park, Nanning District, Guiyang City, which has a building area of 17,521.25 square meters [2]. - The total area of the land parcel is 26,122.49 square meters, designated for industrial use [2][4]. - The land use rights are granted for a period starting from January 15, 2014, to January 15, 2064 [4]. Group 2: Legal and Administrative Aspects - The land use rights have been officially registered, and the company has obtained the "People's Republic of China Real Estate Property Certificate" for the property [2]. - The rights are classified as state-owned construction land use rights with a transfer nature [2].

一心为民 全心服务 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2024年12月26日召开第六届董事会第 七次临时会议，审议通过《关于同意全资子公司贵州鸿翔一心堂医药连锁有限公司对外投资取 得土地使用权及其地上附着物的议案》，同意全资子公司贵州鸿翔一心堂医药连锁有限公司（以 下简称"贵州一心堂"）以自有资金人民币3,280万元投资取得贵州方鸿实业有限责任公司位于 贵阳市双龙新区跨越大道南明区龙洞堡食品工业园A区13号地块分割出来的土地使用权及其地 上附着物。具体内容详见公司2024年12月28日在指定信息披露媒体《证券时报》《中国证券报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）刊登的《关于同意全资子公司贵州鸿翔一心 堂医药连锁有限公司对外投资取得土地使用权及其地上附着物的公告》（公告编号：2024-163 号）。 近日，贵州一心堂已完成土地使用权变更登记事项，并取得坐落于南明区龙洞堡食品工业 园G(13)33号地块的《中华人民共和国不动产权证书》及其地上附着物（建筑物面积17521.2 ...

明日主题前瞻 1、IP经济 | 据上证报，北京乐自天成文化发展股份有限公司(52TOYS)递交招股书，赴港上市，这是港股继名创优品、泡泡玛特、布鲁可、卡游之后，第五 家赴港上市的潮玩企业。 点评：光大证券表示，中国已经成为IP经济的新增长极，在数字技术快速发展的背景下，IP行业正在经历前所未有的变革。《2025-2030年全球及中国IP行业 市场现状调研及发展前景分析报告》的数据显示，2025年中国IP核心市场规模突破1.8万亿元，同比增长率达到16.7%。开源证券表示，2025年国内文化工业 体系完成结构性突围，潮玩与国漫通过IP生态协同实现共生共荣，东方美学正重塑品牌高端化格局。 点评：证券时报指出，稳定币是锚定法定货币等资产以维持价格稳定的加密货币，旨在解决传统加密货币的波动性问题，其核心价值在于强化工具属性而非 投机属性。其价值来源于背后的资产储备（如银行存款、国债），主要充当加密交易的中间媒介和高效跨境支付工具，成为连接传统金融与区块链的桥梁。 截至2025年6月，稳定币市值已达2503亿美元，年交易额高达35万亿美元，规模是Visa年交易量的两倍。 4、固态电池 | 据新浪汽车，在2025香港车展 ...

Market Overview - On June 12, A-shares opened lower with the Shanghai Composite Index down 0.13%, Shenzhen Component Index down 0.37%, and ChiNext Index down 0.23% [1] - The National Index of Free Cash Flow fluctuated downwards, dropping over 0.5%, with constituent stocks showing mixed performance [1] ETF Performance - The low-fee Free Cash Flow ETF (159201) followed the index decline and was actively traded, leading in scale and share among similar products [1] - The fund management fee is set at an annual rate of 0.15%, and the custody fee at 0.05%, both being the lowest in the market, maximizing benefits for investors [1] Investment Strategy - According to Zhongtai Securities, the index remains in a dense trading area, suggesting that the oscillating market may continue [1] - Funds are rapidly rotating around four mid-term trending sectors: dividend assets, safe assets, technology chains, and new consumption [1] - A "reverse layout" strategy is recommended, where significant sector gains indicate a time for profit-taking, while sector adjustments present opportunities for positioning [1] Index Characteristics - The Free Cash Flow ETF (159201) closely tracks the National Index of Free Cash Flow, selecting stocks with positive and high free cash flow after screening for liquidity, industry, and ROE stability [1] - The index is characterized by high quality and strong risk resistance, making it suitable for core portfolio allocation and long-term investment needs [1]

A股医药商业板块水下拉起，一心堂封板涨停，漱玉平民、健之佳、华人健康、第一医药、益丰药房等 跟涨。 ...